GB9723566D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9723566D0
GB9723566D0 GBGB9723566.7A GB9723566A GB9723566D0 GB 9723566 D0 GB9723566 D0 GB 9723566D0 GB 9723566 A GB9723566 A GB 9723566A GB 9723566 D0 GB9723566 D0 GB 9723566D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9723566.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB9723566.7A priority Critical patent/GB9723566D0/en
Publication of GB9723566D0 publication Critical patent/GB9723566D0/en
Priority to APAP/P/2000/001803A priority patent/AP2000001803A0/en
Priority to AT98955538T priority patent/ATE242259T1/de
Priority to CA002309199A priority patent/CA2309199A1/en
Priority to HU0004106A priority patent/HUP0004106A2/hu
Priority to CN98812978A priority patent/CN1285842A/zh
Priority to BR9813973-8A priority patent/BR9813973A/pt
Priority to IL13596598A priority patent/IL135965A0/xx
Priority to EA200000393A priority patent/EA200000393A1/ru
Priority to DE69815378T priority patent/DE69815378T2/de
Priority to AU12327/99A priority patent/AU1232799A/en
Priority to PL98341091A priority patent/PL341091A1/xx
Priority to JP2000520458A priority patent/JP2001522858A/ja
Priority to HR20000276A priority patent/HRP20000276A2/hr
Priority to KR1020007004974A priority patent/KR20010031883A/ko
Priority to PCT/EP1998/007022 priority patent/WO1999024450A2/en
Priority to ES98955538T priority patent/ES2201552T3/es
Priority to EEP200000284A priority patent/EE200000284A/xx
Priority to US09/530,574 priority patent/US6407076B1/en
Priority to TR2000/02157T priority patent/TR200002157T2/xx
Priority to SK671-2000A priority patent/SK6712000A3/sk
Priority to EP98955538A priority patent/EP1027363B1/en
Priority to IS5478A priority patent/IS5478A/is
Priority to NO20002360A priority patent/NO20002360L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB9723566.7A 1997-11-08 1997-11-08 Chemical compounds Ceased GB9723566D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB9723566.7A GB9723566D0 (en) 1997-11-08 1997-11-08 Chemical compounds
EP98955538A EP1027363B1 (en) 1997-11-08 1998-11-06 Adenosine a1-receptor agonists
AU12327/99A AU1232799A (en) 1997-11-08 1998-11-06 Chemical compounds
JP2000520458A JP2001522858A (ja) 1997-11-08 1998-11-06 化合物
CA002309199A CA2309199A1 (en) 1997-11-08 1998-11-06 Adensine a1 receptor agonists
HU0004106A HUP0004106A2 (hu) 1997-11-08 1998-11-06 Új adenozinszármazékok, eljárás előállításukra, azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint ilyen hatóanyagok alkalmazása gyógyszerkészítmények előállítására
CN98812978A CN1285842A (zh) 1997-11-08 1998-11-06 化合物
BR9813973-8A BR9813973A (pt) 1997-11-08 1998-11-06 Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição.
IL13596598A IL135965A0 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists
EA200000393A EA200000393A1 (ru) 1997-11-08 1998-11-06 Химические соединения
DE69815378T DE69815378T2 (de) 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten
APAP/P/2000/001803A AP2000001803A0 (en) 1997-11-08 1998-11-06 Chemical compounds
PL98341091A PL341091A1 (en) 1997-11-08 1998-11-06 Agonists of adenosine receptor a1
AT98955538T ATE242259T1 (de) 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten
HR20000276A HRP20000276A2 (en) 1997-11-08 1998-11-06 Chemical compounds
KR1020007004974A KR20010031883A (ko) 1997-11-08 1998-11-06 화학 화합물
PCT/EP1998/007022 WO1999024450A2 (en) 1997-11-08 1998-11-06 Adensine a1 receptor agonists
ES98955538T ES2201552T3 (es) 1997-11-08 1998-11-06 Agonistas del receptor a1 de la adenosina.
EEP200000284A EE200000284A (et) 1997-11-08 1998-11-06 Keemilised ühendid
US09/530,574 US6407076B1 (en) 1997-11-08 1998-11-06 Adenosine analogues and related method of treatment
TR2000/02157T TR200002157T2 (tr) 1997-11-08 1998-11-06 Kimyasal bileşikler
SK671-2000A SK6712000A3 (en) 1997-11-08 1998-11-06 Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use
IS5478A IS5478A (is) 1997-11-08 2000-05-03 Efnasambönd
NO20002360A NO20002360L (no) 1997-11-08 2000-05-05 Kjemiske forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9723566.7A GB9723566D0 (en) 1997-11-08 1997-11-08 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9723566D0 true GB9723566D0 (en) 1998-01-07

Family

ID=10821742

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9723566.7A Ceased GB9723566D0 (en) 1997-11-08 1997-11-08 Chemical compounds

Country Status (24)

Country Link
US (1) US6407076B1 (enExample)
EP (1) EP1027363B1 (enExample)
JP (1) JP2001522858A (enExample)
KR (1) KR20010031883A (enExample)
CN (1) CN1285842A (enExample)
AP (1) AP2000001803A0 (enExample)
AT (1) ATE242259T1 (enExample)
AU (1) AU1232799A (enExample)
BR (1) BR9813973A (enExample)
CA (1) CA2309199A1 (enExample)
DE (1) DE69815378T2 (enExample)
EA (1) EA200000393A1 (enExample)
EE (1) EE200000284A (enExample)
ES (1) ES2201552T3 (enExample)
GB (1) GB9723566D0 (enExample)
HR (1) HRP20000276A2 (enExample)
HU (1) HUP0004106A2 (enExample)
IL (1) IL135965A0 (enExample)
IS (1) IS5478A (enExample)
NO (1) NO20002360L (enExample)
PL (1) PL341091A1 (enExample)
SK (1) SK6712000A3 (enExample)
TR (1) TR200002157T2 (enExample)
WO (1) WO1999024450A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6784165B1 (en) 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
JP2004505048A (ja) * 2000-08-01 2004-02-19 ユニバーシティー　オブ　ヴァージニア　パテント　ファウンデーション 血管新生を処理するための、選択的アデノシンａ１受容体アゴニスト、アンタゴニストおよびアロステリックエンハンサーの使用
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
JP4514452B2 (ja) * 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2576826C (en) * 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EA025415B1 (ru) 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
KR20130028058A (ko) * 2010-02-03 2013-03-18 엠이에이치 어소시에이츠, 인코포레이티드 선택적 및 생활성 동배체로서의 다수 치환된 플루오로메탄류
EP2569325A4 (en) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp METHOD FOR REDUCING INNER EYE PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA), CPA DERIVATIVES OR PRODRUGS THEREOF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
AU2022597A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Also Published As

Publication number Publication date
US6407076B1 (en) 2002-06-18
HUP0004106A2 (hu) 2001-04-28
CA2309199A1 (en) 1999-05-20
ES2201552T3 (es) 2004-03-16
EE200000284A (et) 2001-08-15
DE69815378T2 (de) 2004-04-29
HRP20000276A2 (en) 2000-12-31
EP1027363A2 (en) 2000-08-16
DE69815378D1 (de) 2003-07-10
EP1027363B1 (en) 2003-06-04
EA200000393A1 (ru) 2000-12-25
SK6712000A3 (en) 2001-01-18
PL341091A1 (en) 2001-03-26
JP2001522858A (ja) 2001-11-20
IL135965A0 (en) 2001-05-20
NO20002360L (no) 2000-07-05
TR200002157T2 (tr) 2000-11-21
AP2000001803A0 (en) 2000-06-30
CN1285842A (zh) 2001-02-28
WO1999024450A2 (en) 1999-05-20
IS5478A (is) 2000-05-03
NO20002360D0 (no) 2000-05-05
WO1999024450A3 (en) 1999-08-19
BR9813973A (pt) 2000-09-26
ATE242259T1 (de) 2003-06-15
KR20010031883A (ko) 2001-04-16
AU1232799A (en) 1999-05-31

Similar Documents

Publication Publication Date Title
GB9705361D0 (en) Chemical compounds
GB9723566D0 (en) Chemical compounds
GB9704208D0 (en) Chemical compounds
GB9717804D0 (en) Chemical compounds
GB9708530D0 (en) Chemical compounds
GB9703201D0 (en) Chemical compounds
GB9708119D0 (en) Chemical compounds
GB9705212D0 (en) Chemical compounds
GB9706707D0 (en) Chemical compounds
GB9711994D0 (en) Chemical compounds
GB9715768D0 (en) Chemical compounds
GB9715661D0 (en) Chemical compounds
GB9708115D0 (en) Chemical compounds
GB9715659D0 (en) Chemical compounds
GB9714831D0 (en) Chemical compounds
GB9714174D0 (en) Chemical compounds
GB9714173D0 (en) Chemical compounds
GB9713908D0 (en) Chemical compounds
GB9713731D0 (en) Chemical compounds
GB9713490D0 (en) Chemical compounds
GB9713410D0 (en) Chemical compounds
GB9712270D0 (en) Chemical compounds
GB9715663D0 (en) Chemical compounds
GB9704182D0 (en) Chemical compounds
GB9711708D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)